



Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
	Applicant Wong		
	Filing Date 09-25-2003	Group Art Unit 1615	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	07/357,394					05/1989
	AB	07/386,835					07/1989
	AC	10/820,563					04/2004
	AD	60/587,092					07/2004
	AE	2004/0019098	01/2004	Andrews, et al.			
	AF	2004/0132824	07/2004	Gil, et al.			
	AG	2004/0137059	07/2004	Nivagioli, et al.			
	AH	2004/0151753	08/2004	Chen			
	AI	2004/0170665	09/2004	Donovan			
	AJ	2004/0266776	12/2004	Gil, et al.			
	AK	2005/0048099	03/2005	Shiah, et al.			
	AL	2005/0058696	03/2005	Donello, et al.			
	AM	2005/0059664	03/2005	Gil, et al.			
	AN	2005/0059744	03/2005	Donello, et al.			
	AO	2005/0101582	05/2005	Lyons, et al.			
	AP	2005/0181017	08/2005	Hughes, et al.			
	AQ	2005/0232966	10/2005	Hughes, et al.			
	AR	2005/0244464	11/2005	Hughes, et al.			
	AS	2005/0244469	11/2005	Whitcup, et al.			
	AT	2005/0244474	11/2005	Huang, et al.			
	AU	2006/0009498	01/2006	Whitcup			
	AV	2006/0233857	10/2006	Whitcup, et al.			
	AW	2006/0233859	10/2006	Whitcup, et al.			
	AX	2007/0224246	09/2007	Hughes, et al.			
	AY	2007/0298073	12/2007	Whitcup, et al.			
	AZ	3,416,530	12/1968	Ness			
	AAA	3,432,592	03/1969	Speiser			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	ABB	3,845,770	11/1974	Theeuwes, et al.			
	ACC	3,914,402	10/1975	Shell			
	ADD	3,916,899	11/1975	Theeuwes, et al.			
	AEE	3,921,632	11/1975	Bardani			
	AFF	3,961,628	06/1976	Arnold			
	AGG	4,008,864	02/1977	Torphammar, et al.			
	AHH	4,014,334	03/1977	Theeuwes, et al.			
	AII	4,063,064	12/1977	Saunders, et al.			
	AJJ	4,088,864	05/1978	Theeuwes, et al.			
	AKK	4,144,317	03/1979	Higuchi, et al.			
	ALL	4,180,646	12/1979	Choi, et al.			
	AMM	4,186,184	01/1980	Zaffaroni			
	ANN	4,200,098	04/1980	Ayer, et al.			
	AOO	4,201,210	05/1980	Hughes, et al.			
	APP	4,285,987	08/1981	Ayer, et al.			
	AQQ	4,300,557	11/1981	Refojo, et al.			
	ARR	4,304,765	12/1981	Shell, et al.			
	ASS	4,327,725	05/1982	Cortese, et al.			
	ATT	4,402,979	09/1983	Shen, et al.			
	AUU	4,451,254	05/1984	Dinius, et al.			
	AVV	4,474,451	10/1984	Mizokami			
	AWW	4,478,818	10/1984	Shell, et al.			
	AXX	4,494,274	01/1985	Thurlow			
	AYY	4,521,210	06/1985	Wong			
	AZZ	4,599,353	07/1986	Bito			
	AAAA	4,668,506	05/1987	Bawa			
	ABBB	4,756,911	07/1988	Drost, et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	ACCC	4,801,460	01/1989	Goertz, et al.			
	ADDD	4,806,337	02/1989	Snipes, et al.			
	AEEE	4,865,846	09/1989	Kaufman			
	AFFF	4,945,089	07/1990	Clark			
	AGGG	4,959,217	09/1990	Sanders, et al.			
	AHHH	4,966,849	10/1990	Vallee, et al.			
	AIII	5,004,601	04/1991	Snipes			
	AJJJ	5,004,614	04/1991	Staniforth			
	AKKK	5,006,342	04/1991	Cleary, et al.			
	ALLL	5,019,400	05/1991	Gombotz			
	AMMM	5,028,624	07/1991	Chan, et al.			
	ANNN	5,034,413	07/1991	Chan, et al.			
	AOOO	5,075,115	12/1991	Brine			
	APPP	5,082,655	01/1992	Snipes, et al.			
	AQQQ	5,169,638	12/1992	Dennis, et al.			
	ARRR	5,268,178	12/1993	Calhoun, et al.			
	ASSS	5,314,419	03/1994	Pelling			
	ATTT	5,322,691	06/1994	Darougar, et al.			
	AUUU	5,330,992	07/1994	Eissenstat, et al.			
	AVVV	5,356,629	10/1994	Sander, et al.			
	AWWW	5,384,333	01/1995	Davis, et al.			
	AXXX	5,385,887	01/1995	Yim, et al.			
	AYYY	5,476,511	12/1995	Gwon, et al.			
	AZZZ	5,597,897	01/1997	Ron, et al.			
	AAAAA	5,601,844	02/1997	Kagayama, et al.			
	ABBBB	5,656,297	08/1997	Bernstein, et al.			
	ACCCC	5,660,847	08/1997	Magruder, et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

### U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	ADDD	5,660,851	08/1997	Domb			
	AEEE	5,688,819	11/1997	Woodward, et al.			
	AFFF	5,693,335	12/1997	Xia, et al.			
	AGGG	5,707,643	01/1998	Ogura			
	AHHH	5,755,785	05/1998	Rowsey, et al.			
	AIII	5,773,019	06/1998	Ashton, et al.			
	AJJJ	5,773,021	06/1998	Gurtler, et al.			
	AKKK	5,824,074	10/1998	Koch			
	ALLL	5,882,682	03/1999	Rork, et al.			
	AMMM	5,902,598	05/1999	Chen, et al.			
	ANNN	5,941,250	08/1999	Aramant, et al.			
	AOOO	5,962,027	10/1999	Hughes			
	APPP	5,972,369	10/1999	Roorda, et al.			
	AQQQ	6,045,791	04/2000	Liu			
	ARRR	6,051,576	04/2000	Ashton, et al.			
	ASSS	6,063,116	05/2000	Kelleher			
	ATTT	6,074,661	06/2000	Olejnuk, et al.			
	AUUU	6,217,911	04/2001	Vaughn, et al.			
	AVVV	6,309,669	10/2001	Setterstrom, et al.			
	AWWW	6,329,369	12/2001	Chow, et al.			
	AXXX	6,331,313	12/2001	Wong, et al.			
	AYYY	6,369,116	04/2002	Wong, et al.			
	AZZZ	6,403,649	06/2002	Woodward, et al.			
	AAAAA	6,497,729	12/2002	Moussy, et al.			
	ABBBB	6,534,542	03/2003	Chow, et al.			
	ACCCC	6,537,568	03/2003	Olejnuk, et al.			
	ADDDD	6,545,182	04/2003	Chow, et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

### U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AEEEEEE	6,699,493	03/2004	Wong			
	AFFFFF	6,713,081	03/2004	Robinson, et al.			
	AGGGGG	6,726,918	04/2004	Wong, et al.			
	AHHHHH	6,841,684	01/2005	Chow, et al.			
	AIIIII	7,048,946	02/1999	Wong, et al.			
	AJJJJJ	7,091,232	08/2006	Chow, et al.			
	AKKKKK	7,141,597	11/2006	Chow, et al.			
	ALLLLL	7,276,522	10/2007	Heidelbaugh, et al.			
	MMMMM	7,335,803	02/2008	Chow, et al.			

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	ANNNNN	CA 1,333,770	10/1988	Canada				
	AOOOOO	CA 2,336,703	01/2000	Canada				
	APPPPP	EP 0 052 916	07/1981	Europe				
	AQQQQQ	EP 0 102 265	03/1984	Europe				
	ARRRRR	EP 0 197 718	03/1986	Europe			X	
	ASSSSS	EP 0 311 065	10/1998	Europe				
	ATTTTT	EP 0 322 319	06/1989	Europe				
	AUUUUU	EP 0 364 417	09/1989	Europe				
	AVVVVV	EP 0 474 098	03/1992	Europe				
	AWWWWW	EP 0 992 244	04/2000	Europe				
	AXXXXX	WO 1991/15495	10/1991	PCT				
	AYYYYY	WO 1991/18940	12/1991	PCT			X	
	AZZZZZ	WO 1992/21660	12/1992	PCT				
	AAAAAAA	WO 1993/10141	05/1993	PCT			X	
	ABBBBBB	WO 1994/03427	02/1994	PCT				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	ACCCCCC	WO 1994/18956	09/1994	PCT				
	ADDDDDD	WO 1994/10202	05/1994	PCT				
	AEEEEEE	WO 1994/14808	07/1994	PCT				
	AFFFFFF	WO 1996/38174	12/1996	PCT			X	
	AGGGGGG	WO 1997/26869	07/1997	PCT			X	
	AHHHHHH	WO 1998/22130	05/1998	PCT				
	AIIIIII	WO 2000/02564	01/2000	PCT			X	
	AJJJJJJ	WO 2000/62760	10/2000	PCT				
	AKKKKKK	WO 2000/56340	09/2000	PCT			X	
	ALLLLLL	WO 2001/30323	05/2001	PCT				
	AMMMMMM	WO 2002/02076	01/2002	PCT				
	ANNNNNN	WO 2002/43785	06/2002	PCT			X	
	AOOOOOO	WO 2003/094888	05/2003	PCT			X	
	APPPPPP	WO 2004/026106	09/2003	PCT			X	
	AQQQQQQ	WO 2004/062649	07/2004	PCT			X	
	ARRRRRR	WO 2005/110362	04/2005	PCT			X	
	ASSSSSS	WO 2006/093758	09/2006	PCT			X	
	ATTTTTT	WO 2007/130945	11/2007	PCT			X	

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AUUUUUU	Aguilar, H.E., et al. "Vancomycin Levels After Intravitreal Injection," <i>Retina</i> , 1995; 15:428-432.
	AVVVVVV	Ahmad, M., et al. "Ortho Ester Hydrolysis: Direct Evidence for a Three-Stage Reaction Mechanism," <i>Journal of American Chemistry</i> , 1979; 101(10):2669-2677.
	AWWWWWW	Ahmed, I., et al. "Macular disorders: cystoid macular edema," <i>Ophthalmology</i> , Yanoff, M., Duker, J.S., eds. London: Mosby, 1999; 34.1-34.6.
	AXXXXXX	Akduman, L., et al. "The early treatment diabetic retinopathy study," <i>Clinical trials in ophthalmology: a summary and practice guide</i> , Kertes, P.S., Conway, M.D., eds. Baltimore: Williams & Wilkins, 1998; 15-35.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AYYYYYYY	Algere, P.V., et al. "Transplantation of RPE in Age-Related Macular Degeneration: Observations in Disciform Lesions and Dry RPE Atrophy," <i>Graefe's Archives of Clinical Experimental Ophthalmology</i> , 1997; 235(3):149-158.
	AZZZZZZ	Anderson, L.C., et al. "An Injectable Sustained Release Fertility Control System," <i>Contraception</i> , 1976; 13:375-384.
	AAAAAAA	Andreau, K., et al. "Induction of apoptosis by dexamethasone in the B cell lineage," <i>Immunopharmacology</i> , 1998 Jul; 40(1):67-76.
	ABBBBBBB	Antcliff, R., et al. "The pathogenesis of edema in diabetic maculopathy," <i>Seminars in Ophthalmology</i> , 1999; 14:223-232.
	ACCCCCC	Araie, M. and Maurice, D.M. "The Loss of Fluorescein, Fluorescein Glucuronide and Fluorescein Isothiocyanate Dextran From the Vitreous by the anterior and Retinal Pathways," <i>Experimental Eye Research</i> , 1991; 52:27-39.
	ADDDDDDD	Baker, R. "Monolithic Devices," <u>Controlled Release of Biologically Active Agents</u> , New York: John Wiley & Sons, 1987; 50-75.
	AEEEEEEE	Barnas, U., et al. "Parameters Associated with Chronic Renal Transplant Failure," <i>Nephrology Dialysis Transplantation</i> , 1997; 12(Suppl 2):82-85.
	AFFFFFFF	Barza, M., et al. "Pharmacokinetics of Intravitreal Carbenicillin, Cefazolin, and Gentamicin in Rhesus Monkeys," <i>Investigative Ophthalmology &amp; Visual Science</i> , 1983; 24:1602-1606.
	AGGGGGGG	Beck, R.W., et al. "The Effect of Corticosteroids for Acute Optic Neuritis on the Subsequent Development of Multiple Sclerosis," <i>New England Journal of Medicine</i> , 1993; 329(24):1764-1769.
	AHHHHHHH	Beck, R.W., et al. "A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis," <i>New England Journal of Medicine</i> , 1992 Feb 27; 326(9):634-5.
	AIIIIIII	Bennett, W.M. and Barry, J.M. "Failure of Dexamethasone to Provide Adequate Chronic Immunosuppression for Renal Transplantation," <i>Transplantation</i> , 1979; 27(3):218-219.
	AJJJJJJJ	Ben-Nun, J., et al. "Pharmacokinetics of Intravitreal Injection," <i>Investigative Ophthalmology &amp; Visual Science</i> 1989; 30(6):1055-1061.
	AKKKKKKK	Bigar, F. and C.P. Herbot. "Corneal Transplantation," <i>Current Opinion in Ophthalmology</i> , 1992; 3(4):473-481.
	ALLLLLLL	Bingaman, D.P., et al. "Inhibition of preretinal neovascularization in pigs by intravitreal triamcinolone acetonide," <i>Investigative Ophthalmology and Visual Science</i> , 1995; 36(4):S401, abstract 1867.
	MMMMMMM	Bito, L.Z. "Prostaglandins and Related Compounds as Potential Ocular Therapeutic Agents," <u>Biological Protection with Prostaglandins</u> , Vol. 1, Cohen, M.M. ed., Boca Raton: CRC Press Inc., 1985; 31-252.
	ANNNNNNN	Bito, L.Z. "Prostaglandins, Other Eicosanoids, and their Derivatives as Potential Antiglaucoma Agents," <u>Glaucoma: Applied Pharmacology in Medical Treatment</u> , Drance, S.M. and Neufled, A.H. Eds., New York: Grune & Stratton, 1984; 477-505.
	AOOOOOOO	Bito, L.Z. "Prostaglandins: Old Concepts and New Perspectives," <i>Archives of Ophthalmology</i> , 1987; 105:1036-1039.
	APPPPPPP	Bolen, J.B. "Nonreceptor tyrosine protein kinases," <i>Oncogene</i> , 1993; 8(8):2025-2031.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AQQQQQQQ	Brubaker, R.F. "Mechanism of Action of Bimatoprost (Lumigan™)," <i>Survey of Ophthalmology</i> , 2001; 45(Suppl 4):S347-S351.
	ARRRRRRR	Budavari, S., et al. eds. <u>The Merck Index</u> , 12 <sup>th</sup> ed. Rahway, NJ: Merck and Co., 1996; Table of Contents only.
	ASSSSSSS	Bundgaard, H. and Møss, J. "Prodrugs of Peptides IV: Bioreversible Derivatization of the Pyroglutamyl Group by N-Acylation and N-Aminomethylation to Effect Protection against Pyroglutamyl Aminopeptidase," <i>Journal of Pharmaceutical Sciences</i> , 1989; 78(2):122-126.
	ATTTTTTT	Burdon, M.A. and P. McDonnell. "A Survey of Corneal Graft Practice in the United Kingdom," <i>Eye</i> , 1995; 9(Suppl):6-12.
	AUUUUUUU	Chacko, D.M., et al. "Survival and Differentiation of Cultured Retinal Progenitors Transplanted in the Subretinal Space of the Rat," <i>Biochemical and Biophysical Research Communications</i> , 2000; 268(3):842-846.
	AVVVVVVV	Challa, J.K., et al. "Exudative Macular Degeneration and Intravitreal Triamcinolone: 18 month follow up," <i>Australian and New Zealand Journal of Ophthalmology</i> , 1998; 26:277-281.
	WWWWWWW	Chang, David, et al. "Phase II results of an intraocular steroid delivery system for cataract surgery," <i>Ophthalmology</i> , 1996 June; 106(6):1172-1177.
	AXXXXXXX	Chang, M., et al. "Basic Science and Clinical Aspects of Wound Healing in Glaucoma Filtering Surgery," <i>Journal of Ocular Pharmacology and Therapeutics</i> , 1998; 14(1):75-95.
	AYYYYYYY	Charles, J., et al. "Use of Bioerodible Polymers Impregnated with Mitomycin in Glaucoma Filtration Surgery in Rabbits," <i>Ophthalmology</i> , 1991 Apr; 98(4):503-508.
	AZZZZZZZ	Chen, J., et al. "Lumigan®: A Novel Drug for Glaucoma Therapy," <i>Optometry in Practice</i> , 2002; 3:95-102.
	AAAAAAAAA	Clarkson, J.G. "Central retinal vein occlusion," <i>Retina</i> , 3 <sup>rd</sup> ed. Ryan, S., Schachar, A.P., eds. St. Louis, MO: CV Mosby; 2001; 1368-1375.
	ABBBBBBBB	Coleman, A.L., et al. "A 3-Month Randomized Controlled Trial of Bimatoprost (LUMIGAN) Versus Combined Timolol and Dorzolamide (Cosopt) in Patients with Glaucoma or Ocular Hypertension," <i>Ophthalmology</i> , 2003; 110(12):2362-2368.
	ACCCCCCCC	Cuff, G. and Raouf, F. "A Preliminary Evaluation of Injection Molding as a Technology to Produce Tablets," <i>Pharmaceutical Technology</i> , 1998; 96-106.
	DDDDDDDD	Davis, P.A., et al. "Intraocular Implant For Controlled 5-Fluorouracil Release," <i>Proceedings of the 19th International Symposium of Controlled Release Bioactive Materials</i> , 1992; 19:339-340.
	AEEEEEEEE	Di Colo, G. "Controlled Drug Release From Implantable Matrices Based On Hydrophobic Polymers," <i>Biomaterials</i> , 1992; 13(12):850-856.
	AFFFFFFFF	Dick, J., et al. "Macular edema," <i>Retina</i> , 3 <sup>rd</sup> ed. Ryan, S., Schachar, A.P., eds. St. Louis, MO: CV Mosby; 2001; 967-979.
	GGGGGGGG	Dinning, W.J. "Intermediate Uveitis: history, terminology definition pars planitis: systemic disease associations," <i>Developments in Ophthalmology: Intermediate Uveitis</i> , W.R.F. Böke, et al. eds. Basel: Karger, 1992; 3-8.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	HHHHHHHH	Druilhe, A., et al. "Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action," <i>Apoptosis</i> , 2003 Oct; 8(5):481-95.
	IIIIIIII	<u>Encyclopedia of Polymer Science and Technology</u> , vol. 3. New York: Interscience Publishers, Inc., 2003; Table of Contents only, v.
	AJJJJJJJ	Enzmann, V., et al. "Immunological Problems of Transplantation into the Subretinal Space," <i>Acta Anatomica</i> , 1998; 162(2-3):178-183.
	KKKKKKKK	Fatt, I. "Flow and Diffusion In the Vitreous Body of The Eye," <i>Bulletin of Mathematical Biology</i> , 1975; 37:85-90.
	ALLLLLLL	Fekrat, S. and Finkelstein, D. "The Central Vein Occlusion Study," <u>Clinical trials in ophthalmology: a summary and practice guide</u> , Kertes, P.S., Conway, M.D., eds. Baltimore, MD: Williams & Wilkins, 1998; 129-143.
	MMMMMMMM	Frank, R.N. "Etiologic mechanisms in diabetic retinopathy," <i>Retina</i> , 3 <sup>rd</sup> ed. Ryan, S., Schachar, A.P., eds. St. Louis, MO: CV Mosby; 2001; 1259-1294.
	NNNNNNNN	Friedrich, S., et al. "Finite Element Modeling of Drug Distribution in the Vitreous Humor of the Rabbit Eye," <i>Annals of Biomedical Engineering</i> , 1997; 25:303-314.
	OOOOOOOO	Gennaro, A.R. ed. <u>Remington: The Science and Practice of Pharmacy</u> , 19 <sup>th</sup> Ed. Easton, PA: Mack Publishing Company, 1995; Table of Contents only, xv-xvi.
	APPPPPPP	Gillies, M.C., et al. "Safety of an intravitreal injection of triamcinolone," <i>Archives of Ophthalmology</i> , 2004 Mar; 122:336-340.
	QQQQQQQQ	Gilman, A.G., et al. eds. <u>Goodman and Gilman's: The Pharmacological Basis of Therapeutics</u> . 8 <sup>th</sup> Ed. New York: Pergamon Press, 1990; Table of Contents only, xi-xvi.
	RRRRRRRR	Goldberg, Ivan, "Drugs for glaucoma," <i>Australian Prescriber</i> , 2002; 25(6)142-146.
	SSSSSSSS	Goodman, L.S. and A. Gilman eds. <u>The Pharmacological Basis of Therapeutics</u> , 9 <sup>th</sup> Ed. New York: McGraw-Hill, 1996; Table of Contents only, v-xii.
	ATTTTTTT	Greenfield, R.S., et al. "Evaluation <i>in Vitro</i> of Adriamycin Immunoconjugates Synthesized Using an Acid-sensitive Hydrazone Linker," <i>Cancer Research</i> , 1990; 50:6600-6607.
	UUUUUUUU	Guan, D., et al. "The Therapeutic Window of Cyclosporine in Chinese Recipients of Renal Transplantation," <i>Transplantation Proceedings</i> , 1995; 27(1):850-851.
	VVVVVVVV	Hari, P. and Srivastava, R.N. "Pulse Corticosteroid Therapy with Methylprednisolone or Dexamethasone," <i>Indian Journal of Pediatrics</i> , 1998; 65(3):557-560.
	WWWWWWW	Hayreh, S.S. "Posterior Drainage of the Intraocular Fluid From the Vitreous," <i>Experimental Eye Research</i> , 1996; 5:123-144.
	XXXXXXXX	Heller, J. "Biodegradable Polymers in Controlled Drug Delivery," <i>CRC Critical Reviews in Therapeutic Drug Carrier Systems</i> , 1984; 1(1):39-90.
	YYYYYYYY	Heller, J. "Bioerodible Hydrogels," <u>Hydrogels in Medicine and Pharmacy</u> , Vol. 3: <u>Properties and Applications</u> , Peppas, N.A. ed. Boca Raton: CRC Press, 1987; 138-149.
	AZZZZZZZ	Heller, J. "Poly (Ortho Esters)," <u>Biopolymers I</u> , Peppas, N.A. and R.S. Langer eds. New York: Springer-Verlag, 1993; 41-92.
	AAAAAAAA	Heller, J., et al. "Poly(ortho ester) Biodegradable Polymer Systems," <u>Methods in Enzymology</u> , Widder, K.J. and R. Green eds. Orlando: Academic Press, Inc., 1985; 422-436.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	BBBBBBBBBB	Hirano, T. "Clinical Significance of Glucocorticoid Pharmacodynamics Assessed by Antilymphocyte Action in Kidney Transplantation," <i>Transplantation</i> , 1994; 57(9):1341-1348.
	CCCCCCCCC	Höckel, M., et al. "Prevention of Peritoneal Adhesions in the Rat With Sustained Intraperitoneal Dexamethasone Delivered by a Novel Therapeutic System," <i>Annales Chirurgiae et Gynaecologiae</i> , 1987; 76(6):306-313.
	DDDDDDDDD	Inoue, M., et al. "Vitreous Concentrations of Triamcinolone Acetonide in Human Eyes After Intravitreal or Subtenon Injection," <i>American Journal of Ophthalmology</i> , 2004; 138(6):1046-8.
	EEEEEEEEEE	Jackanicz, T., et al. "Polyactic Acid As a Biodegradable Carrier for Contraceptive Steroids" <i>Contraception</i> , 1973; 8(3):227-234.
	FFFFFFFFF	Jaffe, G.J., et al. "Safety and Pharmacokinetics of an Intraocular Fluocinolone Acetonide Sustained Delivery Device," <i>Investigative Ophthalmology &amp; Visual Science</i> , 2000; 41(11):3569-3575.
	GGGGGGGGG	Jaffe, G.J., et al. "Safety, Efficacy, and Pharmacokinetics of an Intravitreal Fluocinolone Sustained Drug Delivered System," <i>Investigative Ophthalmology &amp; Visual Science</i> , 1999; 40(4):S988, abstract 5195.
	HHHHHHHHH	Jampel, H., et al. "Glaucoma Filtration Surgery in Monkeys Using 5-Fluorouridine in Polyanhydride Disks," <i>Archives of Ophthalmology</i> , 1990 Mar; 108(3):430-435.
	IIIIIIIII	Jay, W.M., et al. "Intravitreal Ceftazidime in a Rabbit Model: Dose-and Time-Dependent Toxicity and Pharmacokinetic Analysis," <i>Journal of Ocular Pharmacology</i> , 1987; 3(3):257-262.
	AJJJJJJJJ	Jellinek, D., et al. "Inhibition of Receptor binding by High-affinity RNA Ligands to Vascular Endothelial Growth Factor," <i>Biochemistry</i> , 1994; 33:10450-56.
	KKKKKKKKK	Jennings, T., et al. "Posterior sub-Tenon's injections of corticosteroids in uveitis patients with cystoid macular edema," <i>Japanese Journal of Ophthalmology</i> , 1988; 32(4):385-391.
	LLLLLLLLL	Jeong, J.H., et al. "Novel Intracellular Delivery System of Antisense Oligonucleotide by Self-Assembled Hybrid Micelles Composed of DNA/PEG Conjugate and Cationic Fusogenic Peptide," <i>Bioconjugate Chemistry</i> , 2003; 14:473-479.
	MMMMMMMMM	Johnson, F. and Maurice, D. "A Simple Method of Measuring Aqueous Humor Flow With Intravitreal Fluoresceinated Dextran," <i>Experimental Eye Research</i> , 1984; 39:791-805.
	NNNNNNNNN	Jonas, J.B., et al. "Intraocular pressure after intravitreal injection of triamcinolone acetonide," <i>British Journal of Ophthalmology</i> , 2003; 87:24-27.
	OOOOOOOOO	Kane, A., et al. "Intravitreal Injection of Gentamicin in Rabbits," <i>Investigative Ophthalmology &amp; Visual Science</i> , 1981; 20(5):593-597.
	APPPPPPPP	Kang, S.W., et al. "Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema," <i>Archives of Ophthalmology</i> , 2006 May; 124(5):653-8.
	QQQQQQQQQ	Kendall, R.L and K.A. Thomas. "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <i>Proceedings of the National Academy of Science USA</i> , 1994; 90:10705-09.
	RRRRRRRRR	Kher, V., et al. "Low-Dose Dexamethasone- An Alternative Therapy for Acute Renal Allograft Rejection," <i>Transplantation Proceedings</i> , 1992; 24(5):1725.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	ASSSSSSSSS	Kim, K.J., et al. "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <i>Nature</i> , 1993; 362(6423):841-844.
	ATTTTTTTTT	Kimura, H. and Ogura, Y. "Biodegradable Polymers for Ocular Drug Delivery," <i>Ophthalmologica</i> , 2001; 215:143-155.
	UUUUUUUUU	Kinsella, J.L., et al. "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," <i>Experimental Cell Research</i> , 1992; 199:56-62.
	VVVVVVVVV	Kochinke, F. and Wong, V.G. "Biodegradable Drug Delivery System for Uveitis Treatment, Oculex Pharmaceuticals, Inc.," Slide Presentation, 1996; total pages 20.
	VWWWWW	Kralinger, M.T., et al. "Slow Release of Acetylsalicylic Acid by Intravitreal Silicone Oil," <i>Retina: The Journal of Retinal and Vitreous Diseases</i> , 2001; 21(5):513-520.
	XXXXXXXXXX	Kunou, Noriyuki, et al. "Biodegradable scleral implant for controlled intraocular delivery of betamethasone phosphate," <i>Journal of Biomedical Materials Research</i> , 2000; 51(4):635-641.
	AYYYYYYYYY	Laurent, U.B.G. and Fraser, J.R.E. "Turnover of Hyaluronate in the Aqueous Humor And Vitreous Body of the Rabbit," <i>Experimental Eye Research</i> , 1983; 36:493-504.
	AZZZZZZZZZ	Lee, D., et al. "Complications of Subconjunctival 5-Fluorouracil Following Glaucoma Filtering Surgery," <i>Ophthalmic Surgery</i> , 1987 Mar; 18(3):187-190.
	AAAAAAAAAA	Lee, D., et al. "Glaucoma Filtration Surgery in Rabbits Using Bioerodible Polymers and 5-Fluorouracil," <i>Ophthalmology</i> , 1987 Dec; 94(12):1523-1530.
	BBBBBBBBBB	Lee, D., et al. "The Use of Bioerodible Polymers and 5-Fluorouracil in Glaucoma Filtration Surgery," <i>Investigative Ophthalmology &amp; Visual Science</i> , 1988 Nov; 29(11):1692-1697.
	CCCCCCCCC	Lee, K.Y. and Wong, V.G. "Dexamethasone Posterior Segment Drug Delivery System for Treatment of Severe Uveitis," <i>American Uveitis Society</i> , 1999; Abstract.
	DDDDDDDDD	Leopold, I.H. "Nonsteroidal and steroidal anti-inflammatory agents," <u>Surgical pharmacology of the Eye</u> , Sears, M., Tarkkanen, A., eds. New York: Raven Press, 1985; 83-133.
	AEEEEEEEEEE	Marcon, I. "A double-masked comparison of betaxolol and levobunolol for the treatment of primary open-angle glaucoma," <i>Arquivos Brasileiros de Oftalmologia</i> , 1990; 53(1):27-32.
	AFFFFFFFFFF	Mariani, M., et al. "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," <i>Proceedings of the American Association for Cancer Research</i> , 1994; 35:381, abstract 2268.
	GGGGGGGGG	Mathebula, S.D. "A Review of Pharmacological Therapy for Glaucoma," <i>The South African Optometrist</i> , 2005 Sept; 64(3):89-96.
	AHHHHHHHHH	Maurice, D.M. "The Exchange of Sodium Between The Vitreous Body and The Blood And Aqueous Humour," <i>Journal of Physiology</i> , 1957; 137:110-125.
	AIIIIIIII	Maurice, D.M. "Flow of Water Between Aqueous and Vitreous Compartments in the Rabbit Eye," <i>American Journal of Physiology</i> , 1987; 252 (1):F104-F108.
	AJJJJJJJJJ	Maurice, D.M. and Mishima, S. "Ocular Pharmacokinetics," <u>Pharmacology of the Eye</u> , M.L. Sears ed. New York: Springer-Verlag, 1984; 19-116.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	KKKKKKKKKK	Meadows, D.L., et al. "Ocular Drug Delivery with Subconjunctival Implants," <i>Proceedings of the International Symposium on Controlled Release of Bioactive Materials</i> , Controlled Release Society, Inc., 1994; 21:593-594.
	ALLLLLLLLLLL	Migita, K., et al. "Apoptosis Induction in Human Peripheral Blood T Lymphocytes by High-Dose Steroid Therapy", <i>Transplantation</i> , 1997; 63(4):583-587.
	MMMMMMM	Miller, R., et al. "Degradation Rates of Oral Resorbable Implants (Polylactates and Polyglycolates): Rate Modification with Changes in PLA/PGA Copolymer Ratios," <i>Journal of Biomedical Materials Research</i> , 1977; 11(5):711-719.
	ANNNNNNNNNN	Mittal, R., et al. "Treatment of Acute Rejection in Live Related Renal Allograft Recipients: A Comparison of Three Different Protocols," <i>Nephron</i> , 1977; 77(2):186-189.
	AOOOOOOOOOO	Molfino, F., et al. "IOP-lowering effect of dorzolamide 2% versus brimonidine tartrate 0.2%. A prospective randomized cross over study," <i>Investigative Ophthalmology &amp; Visual Science</i> , 1998 Mar; 39(4):S481.
	APPPPPPPPP	Morita, Y., et al. "Polymer Blend Implant for Ocular Delivery of Fluorometholone," <i>Biological &amp; Pharmaceutical Bulletin</i> , 1998; 21(1):72-75.
	QQQQQQQQQ	Moseley, H., et al. "Routes of Clearance of Radioactive Water From The Rabbit Vitreous," <i>British Journal of Ophthalmology</i> , 1984; 68:145-151.
	RRRRRRRRRR	Nauck, M., et al. "Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells," <i>European Journal of Pharmacology</i> , 1998; 341:309-315.
	SSSSSSSSSS	Nauck, M., et al. "Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids," <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1997; 16:398-406.
	TTTTTTTTTT	Nilsson, S.F.E., et al. "PGF2 Increases Uveoscleral Outflow," <i>Investigative Ophthalmology &amp; Visual Science</i> , 1987; 28(3):284, abstract 9.
	UUUUUUUUUU	Ohtori, A. and Tojo, K. "In vivo/in Vitro Correlation of Intravitreal Delivery of Drugs With the Help of Computer Simulation," <i>Biological &amp; Pharmaceutical Bulletin</i> , 1994; 17(2):283-290.
	VVVVVVVVVV	Oplinger, N.L., et al. "A Comparison of Corneal Autografts With Homografts," <i>Ophthalmic Surgery and Lasers</i> , 1998; 29(4):305-308.
	WWWWWW	Orth, D. "The branch vein occlusion study," <u>Clinical trials in ophthalmology: A summary and practice guide</u> , Kertes, P, and Conway, M, eds., Baltimore, MD: Williams & Wilkins, 1998: 113-127.
	XXXXXXXXXX	Patel, N.P., et al. "Indications for and Outcomes of Repeat Penetrating Keratoplasty, 1989-1995," <i>Ophthalmology</i> , 2000; 107(4):719-724.
	YYYYYYYYYY	Pearson, P.A., et al. "Clearance and Distribution of Ciprofloxacin After Intravitreal Injection," <i>Retina</i> , 1993; 13:326-330.
	ZZZZZZZZZZ	Pe'er, J., et al. "Vascular endothelial growth factor by platelet-activating factor upregulation in human central retinal vein occlusion," <i>Ophthalmology</i> , 1998; 105:412-416.
	AAAAAAAAAA	Peyman, G.A. and Herbst, R. "Bacterial endophthalmitis," <i>Archives of Ophthalmology</i> , 1974; 91(5):416-418.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	BBBBBBBBBB	Peyman, G.A., et al. "A Technique for Retinal Pigment Epithelium Transplantation for Age-Related Macular Degeneration Secondary to Extensive Subfoveal Scarring," <i>Ophthalmic Surgery</i> , 1991; 22(2):102-108.
	CCCCCCCCC	Pinar, V. "Intermediate Uveitis," <i>Massachusetts Eye &amp; Ear Infirmary Immunology Service</i> , Boston.
	DDDDDDDDDD	Plowman, G.D., et al. "Receptor Tyrosine Kinases as Targets for Drug Intervention," <i>Drug News &amp; Perspectives</i> , 1994; 7(6): 334-339.
	EEEEEEEEEE	Rahil, J., et al. "Reactivity and Mechanism of Hydrolysis of Phosphoramides," <i>Journal of the American Chemical Society</i> , 1981; 103:1723-1734.
	FFFFFFFFFF	Rao, K.V., et al. "Successful Renal Transplantation in a Patient With Anaphylactic Reaction to Solu-Medrol (Methylprednisolone Sodium Succinate)," <i>American Journal of Medicine</i> , 1982; 72(1):161-163.
	GGGGGGGGGG	Riordan-Eva, P., et al. "Orbital floor steroid injections in the treatment of uveitis," <i>Eye</i> , 1994; 8(1):66-69.
	HHHHHHHHHH	Robin, Jeffrey B., et al. "The Histopathology of Corneal Neovascularization," <i>Archives of Ophthalmology</i> , 1985; 103(2):284-287.
	IIIIIIIIII	Roff, W.J. and Scott, J.R. eds. <u>Handbook of Common Polymers</u> , Cleveland: CRC Press, 1971; Table of Contents.
	AJJJJJJJJJ	Rootman, D.S., et al. "Toxicity and Pharmacokinetics of Intravitreally Injection Ciprofloxacin in Rabbit Eyes," <i>Canadian Journal of Ophthalmology</i> , 1992; 27(6):277-282.
	KKKKKKKKKK	Sasaki, H., et al. "Drug Absorption Behavior After Periocular Injections," <i>Biological &amp; Pharmaceutical Bulletin</i> , 1999; 22(9):956-960.
	LLLLLLLLLL	Schimmer B.P. and Parker K.L. "Adrenocorticotrophic hormone; Adrenocortical Steroids and their Synthetic Analogs; Inhibitors of the Synthesis and Actions of Adrenocortical Hormones," <u>The Pharmacological Basis of Therapeutics 10<sup>th</sup> ed.</u> , Hardman, J.G. and Limbard, L.L. eds, New York: McGraw-Hill, 2001; 1649-1677.
	MMMMMMMM	Schindler, R.H., et al. "The Clearance of Intravitreal Triamcinolone Acetonide," <i>American Journal of Ophthalmology</i> , 1982; 93(4):415-417.
	NNNNNNNNNN	Scholes, G.N., et al. "Clearance of Triamcinolone From Vitreous," <i>Archives of Ophthalmology</i> , 1985; 103(10):1567-1569.
	OOOOOOOOOO	Scott, J.R. and W.J. Roff eds. "Permeability," <u>Handbook of Common Polymers</u> , Cleveland: CRC Press, 1971; 554-558.
	PPPPPPPPPP	Shields, Bruce M. "Glaucoma Filtering Procedures," <u>A Study Guide for Glaucoma</u> , Baltimore: Williams & Wilkins, 1982; 453-476.
	QQQQQQQQQQ	Siebold, et al. <i>Prodrug</i> , 1989; 5:3.
	RRRRRRRRRR	Smith, T., et al. "Sustained-release subconjunctival 5-Fluorouracil," <i>Ophthalmic Surgery and Lasers</i> , 1996 Sept; 27(9):763-767.
	SSSSSSSSSS	Starr, M.S. "Further Studies on the Effect of Prostaglandin on Intraocular Pressure in the Rabbit," <i>Experimental Eye Research</i> , 1971; 11(2):170-177.
	TTTTTTTTTT	Stewart, W., et al. "Washout periods for brimonidine 0.2% and latanoprost 0.005%," <i>American Journal of Ophthalmology</i> , 2001 June; 131(6):798-799.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	UUUUUUUUUU	Taba, K.E., et al. "Intravitreal sustained release fluocinolone implant inhibits experimental choroidal neovascularization," <i>Investigative Ophthalmology &amp; Visual Science</i> , 1999 Mar; 40(4):S172, abstract 920.
	VVVVVVVVVV	Takano, S., et al. "Inhibition of Angiogenesis by a Novel Diaminoanthraquinone that Inhibits Protein Kinase C," <i>Molecular Biology of the Cell</i> , 1993; 4:358A, abstract 2076.
	VWWWWWW	Tan, D.T.H., et al. "Randomized Clinical Trial of a New Dexamethasone Delivery System (Surodex) for Treating of Post-Cataract Surgery Inflammation," <i>Ophthalmology</i> , 1999; 106(2):223-231.
	XXXXXXXXXX	Tennant, J.L. "Cystoid maculopathy," <u>Current concepts in cataract surgery: selected proceedings of the fifth biennial cataract surgical congress</u> , Emery, J.M. ed. St. Louis: CV Mosby, 1978; 360-362.
	YYYYYYYYYY	Theng, J.T.S., et al. "Pharmacokinetic and Toxicity Study of an Intraocular Cyclosporine DDS in the Anterior Segment of Rabbit Eyes," <i>Investigative Ophthalmology &amp; Visual Science</i> , 2003 Nov; 44(11):4895-4899.
	ZZZZZZZZZZ	Tsubota, K. "Ocular Surface Management in Corneal Transplantation, A Review," <i>Japanese Journal of Ophthalmology</i> , 1999; 43(6):502-508.
	AAAAAAAAA	Turcotte, J.G., et al. "Rejection Crises in Human Renal Transplant Recipients: Control with High Dose Methylprednisolone Therapy," <i>Archives of Surgery</i> , 1972; 105(1):230-236.
	BBBBBBBBBB	<u>The United States Pharmacopeia, The National Formulary</u> , "USP 24/NF 19," 2000; 1941-1951.
	CCCCCCCCC	Watson, P., et al. "A Six-month, Randomized, Double-masked Study Comparing Latanoprost with Timolol in Open-angle Glaucoma and Ocular Hypertension," <i>Ophthalmology</i> , 1996; 103(1):126-137.
	DDDDDDDD	Weisbecker, C.A., et al., eds. <u>Physicians' Desk Reference for Ophthalmology 27<sup>th</sup> ed.</u> , Montvale, NJ: Medical Economics Company, 1998; 7-8, 278-279.
	EEEEEEEEEE	Wingate, R.J., et al. "Intravitreal Triamcinolone and Elevated Intraocular Pressure," <i>Australian and New Zealand Journal of Ophthalmology</i> , 1999 Dec; 27(6):431-2.
	FFFFFFF	Woodward, D.F., et al. "AGN 192024 (Lumigan®): A Synthetic Prostanoid Analog that Lowers Primate Intraocular Pressure by Virtue of Its Inherent Pharmacological Activity," <i>Investigative Ophthalmology &amp; Visual Science</i> , 2002; 43, abstract 4110.
	GGGGGGGGG	Woodward, D.F., et al. "The Pharmacology of Bimatoprost (Lumigan™)," <i>Survey of Ophthalmology</i> , 2001; 45(Suppl 4):S337-S345.
	HHHHHHHHH	Wright, P.S., et al. "Inhibition of Angiogenesis In Vitro and In Ovo with an Inhibitor of Cellular Protein Kinases, MDL 27032," <i>Journal of Cellular Physiology</i> , 1992; 152(3):448-457.
	IIIIIIIIII	Xu, J., et al. "Permeability and Diffusion in Vitreous Humor: Implications for Drug Delivery," <i>Pharmaceutical Research</i> , 2000; 17(6):664-669.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	